Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of JNJ-89402638 in metastatic colorectal cancer and other gastrointestinal malignancies
jRCT2041260049Phase 1Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of JNJ-89402638 in colorectal adenocarcinoma, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Janssen Pharmaceutical. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
JNJ-89402638
03
Conditions
colorectal adenocarcinomagastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2041260049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260049.